NEW YORK, May 7, 2012 /PRNewswire/ -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, today announced that its May 3rd RetailInvestorConferences.com presentation is now available for on-demand viewing.
LINK: www.retailinvestorconferences.com > red "register/ watch event now" button
Provectus Pharmaceuticals, Inc's presentation will be available for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.
About Provectus Pharmaceuticals Inc.
Provectus Pharmaceuticals (PVCT) specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.
Since 2010, RetailInvestorConferences.com, created by BetterInvesting (NAIC) PR Newswire and MUNCmedia, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
|SOURCE Provectus Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved